Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Fat Malabsorption in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Chronic Plaque Psoriasis
Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001
Phase 2 N=80 Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
Stage V Chronic Kidney Disease
Primary: Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation — 7; 73; 3; 4 Participants — p=< 0.001
Phase 2 N=332 Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Fracture Healing
Primary: Timed-Up-and-Go (TUG) Over Week 6 Through Week 20 — 54.1; 41.0; 47.2; 53.3 seconds — p=0.1983
Phase 2 N=20 SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Malignant Peripheral Nerve Sheath Tumors (MPNST) · Sarcoma
Primary: Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. — 0; 1 DLTs
Phase 2 N=50 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Acute Myelogenous Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1…
Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Phase 2 N=157 A Phase2 of A-101 Topical Solution in Subjects With Common Warts
Common Wart
Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)
Phase 2 N=170 Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants
Environmental Carcinogenesis
Primary: Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples — 24.8; 11.0; 4.3 micromoles/24 hours — p=<0.001
Phase 2 N=402 Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Fracture Healing
Primary: Time to Radiographic Healing — 16.4; 18.6; 18.3; 18.2 weeks — p=0.3598
Phase 2 N=24 Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
Bilateral Knee Osteoarthritis
Primary: Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma — 1801.5; 4507.9; 1893.6; 5140.1 pg/mL
Phase 2 N=195 Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Castration Resistant Metastatic Prostate Cancer
Primary: Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic Progression — 5.62; 5.72 months
Phase 2 N=105 Randomized Double Cord Blood Transplant Study
Leukemia, Lymphocytic, Acute · Leukemia, Myelocytic, Acute · Leukemia, Myeloid, Chronic
Primary: Time To Neutrophil Engraftment — 17; 15 Days
Phase 2 N=20 To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
Primary Bile Acid Diarrhea
Primary: Number of Patients Reported With Adverse Events , Serious Adverse Events and Death. — 9; 14; 0; 4 count of participants